［1］指导肾性贫血患者自我管理的中国专家共识工作组, 左力, 朱丽. 指导肾性贫血患者自我管理的中国专家共识(2024版)［J］. 中国血液净化, 2025, 24(1): 1-12.
［2］血管紧张素受体-脑啡肽酶抑制剂在慢性肾脏病患者中应用的中国专家共识专家组, 甘良英, 左力. 血管紧张素受体-脑啡肽酶抑制剂在慢性肾脏病患者中应用的中国专家共识［J］. 中国血液净化,2023,22(4): 241-253.
［3］拟钙剂治疗MHD患者SHPT专家共识工作组, 左力, 甘良英. 拟钙剂治疗维持性血液透析患者继发性甲状旁腺功能亢进症的中国专家共识(2024版)［J］. 中国血液净化, 2024,23(10): 721-735.
［4］左力, 王磊. 连续性肾脏替代治疗置换液临床应用分类专家共识［J］. 中国血液净化, 2023,22(10): 721-725.
［5］Gan L, Lyu X, Yang X, et al. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus［J］. Front Med (Lausanne), 2022, 9: 877237.
［6］慢性肾脏病高血压管理共识专家组. 非透析和透析慢性肾脏病患者高血压管理的中国专家共识［J］. 中华内科杂志, 2023,62(7): 748-774.
［7］Zhao X, Niu Q, Gan L, et al. Baseline data report of the China Dialysis Outcomes and Practice Patterns Study (DOPPS)［J］. Sci Rep, 2021, 11(1): 873.
［8］Cheng X, Nayyar S, Wang M, et al. Mortality rates among prevalent hemodialysis patients in Beijing: a comparison with USRDS data［J］. Nephrol Dial Transplant, 2013, 28(3): 724-732.
［9］Zhao X, Niu Q, Gan L, et al. Blood flow rate: an independent risk factor of mortality in Chinese hemodialysis patients［J］. Semin Dial, 2022,35(3): 251-257.
［10］Zhao X, Hou FF, Liang X, et al. High facility-level serum potassium variability associated with mortality in hemodialysis patients: results from Chinese Dialysis Outcomes and Practice Patterns Study (DOPPS)［J］. Ren Fail, 2023, 45(1): 2211157.
|
